News
FDA Approves Erdafitinib for Advanced Bladder Cancer
During the presentation, Daniel P. Petrylak, MD, an ASCO discussant and the chief of genitourinary oncology at Yale Cancer Center in New Haven, Connecticut, stressed the importance of genetic testing. “I think the most important take-home message for the day is that all patients with metastatic [UC] should need to be tested for FGFR3 or FGFR2 alterations,” he said.
Source: OBR Oncology